MANNKIND CORP Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
MANNKIND CORP (MNKD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- MANNKIND CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $2.44, a 10.95% decline from fiscal 2024.
- MANNKIND CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $2.74, a 8.30% increase from fiscal 2023.
- MANNKIND CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $2.53, a 39.01% increase from fiscal 2022.
- MANNKIND CORP share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $1.82, a 14.47% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2026-06-30 | $2.44 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $2.44 10-K · filed 2026-02-26 | |
| 2024-12-31 | $2.74 10-K · filed 2025-02-26 | |
| 2023-12-31 | $2.53 10-K · filed 2024-02-27 | |
| 2022-12-31 | $1.82 10-K · filed 2023-02-23 | |
| 2021-12-31 | $1.59 10-K · filed 2022-02-24 | |
| 2020-12-31 | $1.55 10-K · filed 2021-02-25 | |
| 2019-12-31 | $2.25 10-K · filed 2020-02-25 | |
| 2018-12-31 | $2.87 10-K · filed 2019-02-26 | |
| 2017-12-31 | $3.17 10-K · filed 2018-02-27 | |
| 2016-12-31 | $13.60 10-K · filed 2017-03-16 | |
| 2015-12-31 | $5.78 10-K · filed 2016-03-15 | |
| 2014-12-31 | $4.54 10-K · filed 2015-03-02 | |
| 2013-12-31 | $2.93 10-K · filed 2014-03-03 | |
| 2012-12-31 | $3.96 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |